1	Clinical presentation, disease course and outcome of COVID-19 in
2	hospitalized patients with and without pre-existing cardiac disease - a
3	cohort study across eighteen countries
4	
5	Authors:
6	CAPACITY-COVID collaborative consortium and LEOSS Study Group*
7	*Authors listed at the end of the manuscript
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	Word count (max 5000): 4784
26	Corresponding author
27	Prof. Dr. Folkert W. Asselbergs
28	E-mail: <u>f.w.asselbergs@umcutrecht.nl</u>
29	Department of Cardiology, Division Heart & Lungs University Medical Center Utrecht
30	Room E03.511 P.O. Box 8550 3508 GA Utrecht, The Netherlands
31 32	T +31 8875561 76 Pager 4711 via +31 887555555 F +31 88755542

1 Abstract (250 max)

Aims Patients with cardiac disease are considered high risk for poor outcomes following hospitalization with
 COVID-19. The primary aim of this study was to evaluate heterogeneity in associations between various heart
 disease subtypes and in-hospital mortality.

5

6 Method and results We used data from the CAPACITY-COVID registry and LEOSS study. Multivariable 7 Poisson regression models were fitted to assess the association between different types of pre-existent heart 8 disease and in-hospital mortality. 16,511 patients with COVID-19 were included (21.1% aged 66 - 75 years; 9 40.2% female) and 31.5% had a history of heart disease. Patients with heart disease were older, predominantly 10 male and often had other comorbid conditions when compared to those without. Mortality was higher in patients 11 with cardiac disease (29.7%; n=1545 versus 15.9%; n=1797). However, following multivariable adjustment this 12 difference was not significant (adjusted risk ratio (aRR) 1.08 [95% CI 1.02 - 1.15; p-value 0.12 (corrected for 13 multiple testing)]). Associations with in-hospital mortality by heart disease subtypes differed considerably, with 14 the strongest association for heart failure aRR (1.19 [1.10 - 1.30]; p-value < 0.018) particularly for severe 15 NYHA III/IV) heart failure (aRR 1.41 [95% CI 1.20 - 1.64; p-value <0.018]. None of the other heart disease 16 subtypes, including ischemic heart disease, remained significant after multivariable adjustment. Serious cardiac 17 complications were diagnosed in <1% of patients.

18

19 Conclusion Considerable heterogeneity exists in the strength of association between heart disease subtypes and 20 in-hospital mortality. Of all patients with heart disease, those with heart failure are at greatest risk of death when 21 hospitalized with COVID-19. Serious cardiac complications are rare.

22

23 Key words

- 24 COVID-19; SARS-CoV-2; epidemiology; patient registry; comorbidity; cardiovascular disease
- 25
- 26
- 27
- 28 29
- 30

1 Introduction

2 Coronavirus disease 2019 (COVID-19) has rapidly spread across the globe since December 2019, leading to 3 more than 175 million confirmed cases and 3.5 million fatalities as of the 18^{th} of June 2021.¹ Although the 4 disease is not as lethal (case fatality ratio (CFR) ~0.3 - 1%)^{2,3} as the Middle-East respiratory syndrome (MERS; 5 CFR ~35%)⁴ and the severe acute respiratory syndrome (SARS; CFR 14 – 15%)⁵, it has become clear that 6 morbidity and mortality is much higher than pandemic influenza (CFR 0.1%)^{6,7}, especially among the elderly³.

7 Studies show that a significant number of patients who develop severe symptoms of COVID-19 have 8 underlying comorbidities, of which cardiovascular disease (CVD) is reported in 10 - 30% of inpatients in 9 Western-European and American cohorts.⁸⁻¹¹ Patients with pre-existing cardiac disease have consistently been 10 reported to be at increased risk of an unfavorable outcome both among the general population and those 11 requiring hospitalization when compared to patient without these conditions.^{8,12} In one of the largest cohort 12 studies of hospitalized patients thus far (n=20,133), chronic cardiac disease was significantly associated with 13 mortality (adjusted HR 1.16; 95% confidence interval (CI) 1.08 - 1.24).⁸ Another study by Fried et al. 14 (n=11,721) across 38 states in the United States, found an adjusted odds ratio (aOR) of 1.22 (95% CI 1.06 -15 1.41) and 1.44 (95% CI 1.27 - 1.63) for mechanical ventilation and death respectively related to cardiac 16 disease.¹¹ The Chinese Center for Disease Control report a CFR five times higher among those with CVD 17 compared to patients without any comorbidities.¹³ These observations are in line with previous studies among patients with influenza and other respiratory tract infections.¹⁴⁻¹⁵ 18

19 Previous studies have predominantly evaluated the association between having any chronic cardiac 20 disease and COVID-19 related mortality, where all cardiac disease subtypes are analyzed together.^{8,11,12} 21 However, from a clinical point of view, it is likely that not all cardiac diseases mediate a similar risk. Increasing 22 our understanding of the clinical course of COVID-19 in patients across different heart disease subtypes is of 23 pivotal importance. Firstly, it can provide guidance for health care professionals in the management of these 24 patients and would better inform shielding guidelines. Secondly, it can bring some clarity for patients, 25 concerned about how their own cardiac disease influences their risk from COVID-19.16 Reducing these 26 concerns might also have a positive impact on health care seeking behavior during the pandemic, diminishing 27 the detrimental collateral damage the outbreak has provoked in patients with heart disease who are afraid of 28 attending hospitals.¹⁷

The aim of the current study was to investigate whether there is heterogeneity in the strength of association per heart disease subtype and in-hospital mortality. Furthermore, we describe the disease trajectory

1 of COVID-19 in hospitalized patients with- and without pre-existing cardiac disease, from documentation at

2 hospital admission to discharge or death, including the prevalence of cardiac complications.

3

4 Methods

5

6 *Study design and setting*

For this study we used data collected in the CAPACITY-COVID registry (<u>www.capacity-covid.eu</u>) and the
Lean Open Survey on SARS-CoV-2 infected patients (LEOSS) study (www.LEOSS.net).

9 CAPACITY-COVID is a multinational patient registry specifically established to determine the role of 10 CVD in the COVID-19 pandemic (NCT04325412).¹⁸ All adult patients (≥18 years) hospitalized with confirmed 11 or highly suspected COVID-19 are eligible for inclusion in the registry. The extent and scope of inclusion varies 12 per site, depending on local resources and preference. A majority of participating centers (n=56) use a non-13 selective inclusion, i.e., every adult patient with (highly suspected) COVID-19 or a random sample is included 14 in the registry, and 18 centers applied a selective inclusion of only patients for whom a cardiologist has been 15 consulted, only patients with a history of CVD or cardiovascular risk factors or a selection based on department 16 of admission i.e., only patients admitted to the ward or intensive care unit (ICU). Since the launch of the registry 17 in March 2020, 74 centers across 13 countries have joined the consortium.

Within CAPACITY-COVID, the ISARIC core case report form¹⁹ has been used as the core data set which was extended with ~400 additional variables to capture in-depth information regarding cardiovascular history, the use of cardiovascular medications, cardiac investigations such as ECG and echocardiography and cardiovascular outcomes. The data dictionary is available online (www.capacity-covid.eu). Only data generated during routine clinical care is collected and patients do not undergo any additional investigations for the purpose of this registry. Data is collected in a REDCap database after pseudonymization which is managed by the University Medical Center Utrecht, Utrecht, the Netherlands.

Variable definitions handled in CAPACITY-COVID are incorporated in the REDCap Case Report Form (CRF) and can be found online among the study documents at: <u>https://capacity-covid.eu/for -</u> professionals/. For the registration of cardiac complication, the diagnostic criteria of the European Society of Cardiology (ESC) guidelines for myocarditis²⁰, pericarditis²¹ endocarditis²² and acute coronary syndrome²³ were incorporated to minimize heterogeneity in the adjudication of these events. For arrhythmia's, the ACC/AHA/HRS 2006 key data elements and definitions for electrophysiological studies and procedures was

used.²⁴ In absence of a definition, a clinical diagnosis as indicated in the Electronic Health Record (EHR) was
 handled.

3 LEOSS is a European multicenter cohort study established in March 2020, collecting information on 4 both hospitalized and ambulant patients with laboratory confirmed COVID-19. A detailed description of the 5 study design has been previously reported.²⁵ In short, patients of all ages can be included in LEOSS. Case 6 collection is anonymized, realized by amongst other the absence of any variables containing directly identifying 7 information in the case report form, only a small subset of variables associated with a high risk of re-8 identification and the categorized collection of continuous variables (such as age).²⁶ The CRF of LEOSS can be 9 provided upon request. Currently centers from Austria, Belgium, Bosnia and Herzegovina, Germany, Italy, 10 Latvia Spain, Switzerland, Turkey and the United Kingdom contribute data to the registry. The data collection is 11 coordinated by the University Hospital of Cologne in Germany.

12

13 Study population

14 We excluded patients only treated in an ambulatory setting, children (age <18 years) and patients for which the 15 region of inclusion, COVID-19 status, admission date, history of cardiac disease, age, sex or outcome were 16 unconfirmed. All hospitalized patients aged \geq 18 years with a laboratory confirmed SARS-CoV-2 infection 17 registered between March and May 2021 were included. A list of all participating sites that contributed with 18 data to the current study is provided in Table S1. The informed consent procedure varied per study site, 19 following local and national rules and regulations during the pandemic. Within CAPACITY-COVID, a majority 20 of participating sites handled an opt-out approach, where patients received written information during or after 21 hospital admission. For sites in the UK, informed consent was not required under emergency legislation during 22 the pandemic. Inclusion into LEOSS did not require informed consent due to anonymous case collection. 23 Medical ethics approval was obtained nationally or independently for each participating site complying with the 24 Declaration of Helsinki.

25

26 Statistical analysis

27 Continuous variables in CAPACITY-COVID were categorized to align with LEOSS prior to merging the 28 datasets from these two different sources. Multiple imputation (R package *mice*) was performed to deal with 29 missingness across baseline variables required for the regression models through the generation of 10 imputed 30 datasets. The following variables were included in the multiple imputation model: all variables indicated with an

asterisk in **Table 1-3**, and furthermore presence of pre-existing cardiac disease, arrhythmia/conduction disorder,
 heart failure, coronary artery disease (CAD), valvular heart disease, month and year of hospital admission,
 extent of inclusion (all/random sample vs. selected inclusion as described above), cohort (CAPACITY-COVID
 vs. LEOSS) and region of inclusion (Central Europe, Netherlands/Belgium, Middle – East, Southern-Europe
 and the United Kingdom). Baseline variables with >40% missingness were excluded from further analysis.

6 For the main analyses, multivariable modified Poisson models with robust standard errors were used to 7 estimate the association between a history of cardiac disease and in-hospital mortality across the pooled ten 8 imputed datasets. Heterogeneity in associations was also determined across various clinically relevant 9 subgroups including age (\leq 65 and >65), sex, body mass index (BMI) (<30 and \geq 30), diabetes, hypertension, 10 chronic kidney disease (CKD) and chronic obstructive pulmonary disease (COPD). In the secondary analyses, 11 associations between pre-defined specific types of heart disease and the in-hospital mortality were determined. 12 The following heart disease subtypes were analyzed: arrhythmias/conduction disorders, CAD, myocardial 13 infarction (MI), heart failure and valvular heart disease. To be able to determine differences in the association 14 between the pre-defined cardiac disease subtypes and in-hospital mortality in adults versus the elderly, analyses 15 were also performed in patients ≤65 years and >65 years. The cut-off was set at 65 since most COVID-19 16 vaccination strategies in Europe have defined the elderly as those >65 years of age.²⁷

All analyses were adjusted for the following covariates: age, sex, BMI, diabetes, hypertension, CKD, COPD and geographic region of inclusion (see above). For the sensitivity analyses we excluded patients included by centers handling a selective inclusion strategy as previously outlined. In addition, we assessed the direction and magnitude of the associations based on registry of inclusion (CAPACITY vs. LEOSS), next to fitting models in the dataset of the combined cohorts.

Logistic regression on the non-imputed dataset was used to identify association of the most prevalent COVID-19 symptoms at presentation and eight different age categories in the total cohort and after stratification on pre-existent cardiac disease. Due to low numbers of young patients with a history of cardiac disease, the four lowest age categories were merged in the stratified analyses (18 – 55 years).

Results of the modified Poisson regression models are reported as risk ratios (RR) with 95% confidence intervals (CI)) and the logistic regression models as odds ratios (ORs) with 95% CI's. Statistical significance was set at an alpha of 5% and all hypothesis tests were two-sided. The regression analyses were corrected for multiple testing using the Holm-Bonferroni method. Continuous variables were summarized as

1 means (SD) or medians [IQR] and categorical variables as counts (%). All analyses were performed in R Studio

- 2 (version 1.3.959, Vienna, Austria).
- 3
- 4 **Results**
- 5

6	Baseline	character	ristics

In total, 20,954 patients had been included in CAPACITY-COVID or LEOSS between March and May 2021.
After applying exclusion criteria, 16,511 patients from eighteen countries were retained for the final analysis
(Figure S1). Baseline characteristics stratified by the presence of pre-existing cardiac disease and age are
summarized in Table 1.

Most patients were aged between 76 – 85 (n=3,720; 22.5%), and more than half the cohort was composed of individuals >65 years (n=8,861; 53.7%). Most patients were white (n=12,120; 84.5%), predominantly male (n=9,864; 59.8%), and 68.0% (n=7,080 had a BMI >25 kg/m². At baseline, almost one third of patients (n=5,198; 31.5%) had pre-existing heart disease of which cardiac arrhythmias/conduction disorders (n=2,503; 15.3%) and CAD (n=2,420; 14.8%) were most common (**Table S2**). In total, 1,314 patients (8.1%) had been previously diagnosed with heart failure. Other frequent major comorbidities were diabetes (n=4,031; 24.9%) and CKD (n=2,196; 13.5%).

Compared to patients without a history of cardiac disease, patients with pre-existing heart disease were generally older, more often male (63.6% vs. 58.1%) and had a higher burden of cardiovascular risk factors and other comorbid conditions at baseline (**Table 1**). Detailed phenotyping of underlying pre-existing cardiac diseases of patients registered in CAPACITY-COVID, including arrhythmias, conduction disorders, type of ischemic- and valvular heart disease are outlined in **Table S3**. To evaluate heterogeneity across datasets, baseline characteristics were also stratified by the cohort of origin (CAPACITY-COVID vs. LEOSS; **Table S2**). Patients in LEOSS tended to be younger with an overall higher prevalence of heart disease.

25

26 Complaints at admission

The median duration from the onset of symptoms to hospital admission was 6 days [IQR 2 - 9]. Fever, cough and shortness of breath were the most common symptoms at presentation reported in 54.9%, 51.8% and 49.8% of patients respectively (**Table 2**). The odds of having these symptoms varied across age, with fever, cough and dyspnea being reported less frequently in the younger (<45 years) and older (>65 years) age groups (**Figure S2**).

The probability of experiencing a sore throat, anosmia and chest pain declined with age, while fatigue was reported more often with increasing age. Heterogeneity in complaints and vital signs at admission was also assessed by stratification by cohort of inclusion (CAPACITY-COVID vs. LEOSS; **Table S4**). Of symptoms overlapping with CVD, chest pain was most common, reported by 9.2% of patients. Less than five percent of patients experienced (pre) syncope, palpitations, orthopnea or peripheral edema (**Table S4**). After stratification by age, the pattern of complaints did not differ between patients with and without a history of cardiac disease (**Figure S3**).

8

9 Outcomes

10 The median duration of hospital admission was 9 [5 - 18] days (**Table 3**). More than one in four patients were 11 admitted to a critical care unit (n=3916; 27.6%) with a median length of stay of 12 [6-23] days. The proportion 12 of patients admitted to a critical care unit increased with age until 75 years. Patients aged >75 years were 13 predominantly treated on the ward (Table S5). Overall, the comorbidity burden among patients on a critical care 14 unit was lower than for patients admitted to the ward only (Table S5). Patients that were admitted to a critical 15 care unit tended to be more ill at admission based on vitals and laboratory values at hospital admission (Table 16 **S6**). During hospital admission 20.2% (n=3342) of patients died. Mortality was strongly related to age, with a 17 mortality of 0.8% (n=2) in patients aged 18-25 years and 39.4% (n=652) in patients aged >85 years (Table S7). 18 Oxygen saturation levels were lower at admission in those who died, while the levels of inflammatory markers 19 (C-reactive protein and total white blood cell count) were higher (Table S8). In patients with cardiac disease 20 29.7% (n=1545) died during their hospital admission versus 15.9% (n=1797) in patients without chronic heart 21 disease (Table 3). In addition to heart disease, other comorbidities were also more prevalent in patients that died 22 during their hospital admission (Table S7).

23

24 Cardiac and thromboembolic complications

During hospitalization, serious cardiac complications including myocarditis, MI and new onset heart failure were diagnosed in 0.2% (n=37), 0.6% (n=95) and 1.2% (n=197) of patients respectively (**Table 3**). Other serious cardiac complications registered only in CAPACITY-COVID, including malignant ventricular arrhythmias, endocarditis and pericarditis were also uncommonly diagnosed (<1% of patients; **Table S9**). MI and new onset heart failure was diagnosed more frequently in patients with pre-existing cardiac disease compared to those without (**Table 3**). Among thromboembolic complications, pulmonary embolism was most

prevalent being diagnosed in 3.5% (n=569) of patients (**Table 3**). All complications occurred more often in patients admitted to a critical care unit and patients that died in-hospital (**Table S10, S11**), with the difference being most pronounced for pulmonary embolism, which was diagnosed in 10.5% (n=405) the critically ill vs. 1.4 (n=144) among patients only admitted to the ward. Venous thromboembolic complications were diagnosed less frequently among patients with a history of heart disease (**Table 3**).

6

7 Association between prior history of cardiac disease and in-hospital mortality

8 The multivariable modified Poisson regression model fitted in the total population yielded a non-statistically
9 significant association between any pre-existing cardiac disease and in-hospital mortality (aRR 1.08 [95% CI
10 1.02

11 1.15, p-value 0.12])(Figure 1). This association was further explored across different clinically relevant 12 subgroups (Table S12). Apart from age and sex, displaying a trend towards an interaction with prior heart 13 disease (p-value 0.10 and 0.09 respectively), the subgroup analyses did not reveal any other interactions. 14 Furthermore, sensitivity analyses by the exclusion of patients included from centers that handled a selective 15 inclusion (n=707) did not yield any different results (Table S13).

16

17 Association between different pre-existing cardiac comorbidities and in-hospital mortality

To assess heterogeneity in the associations between different types of heart disease and hospital mortality, modified Poisson regression models were fitted for all pre-specified cardiac disease subgroups. After multivariable adjustment, the strongest association was found for heart failure and in-hospital mortality (aRR 1.19 [95% CI 1.10 – 1.30; p-value <0.018] and in particular for severe (NYHA III/IV) heart failure (aRR 1.41 [95% CI 1.20 – 1.64; p-value <0.018)(**Figure 1**). For the other heart disease subtypes, including ischaemic heart disease, no significant associations with in-hospital mortality were found (**Figure 1**, **Table S14**).

Since the elderly (>65 years) and adults with comorbidities are defined as two of the main risk groups being prioritized in ongoing vaccination campaigns and statistical interaction was established between preexisting cardiac disease and age, associations between the various heart disease subtypes and in-hospital mortality were also determined in patients ≤ 65 years and ≥ 65 years (Figure 2). However, for none of the heart disease subtypes the interaction with age was found significant. As heterogeneity in treatment intensity may impact the associations between pre-existing heart disease and in-hospitals, we also performed a separate analysis in patients admitted only to the wards vs. patients admitted to a critical care unit. A strong interaction

1 was found between having any history of cardiac disease, arrhythmia/conduction disorders, valvular heart 2 disease and admission to a critical care unit (**Table S15**). The adjusted RR's between these pre-existing heart 3 conditions and in-hospital mortality overall were lower in patients that had been admitted to a critical care unit 4 when compared to patients only admitted to the ward.

5

6 Discussion

7 A large proportion of patients developing severe COVID-19 have underlying CVD. The aim of this study was to 8 describe and compare the disease course and outcomes in hospitalized COVID-19 patients with and without pre-9 existing cardiac disease. The most important findings of this work are (i) the symptoms of COVID-19 at 10 presentation are age dependent and do not differ in individuals with and without prior cardiac disease (ii) serious 11 incident cardiac complications are diagnosed infrequently during hospitalization and are seen more often in 12 patients with known cardiac disease at baseline (iii) the association between prior heart disease and in-hospital 13 mortality varies across heart disease subtypes where (iv) heart failure associates most strongly with in-hospital 14 mortality and (v) there was no association with ischemic heart disease.

15 In line with others²⁸, we found that COVID-19 symptoms at admission vary mainly with age with no 16 evidence that prior cardiac disease influences this relationship or the symptoms. Typical symptoms of COVID-17 19 including fever, cough and shortness of breath, were reported less often in the elderly. Overall complaints 18 mimicking cardiac disease, such as chest pain, palpitations and orthopnea were reported by only a minority of 19 patients (<10%). In this regard, it is interesting that cardiac-like symptoms such as chest pain and palpitations 20 have been reported by 17-44% and 20-32% of patients in the 2-3 months after the active infection as part of the 21 so-called "long COVID" syndrome.²⁹⁻³² Whether these complaints are related to cardiovascular involvement in 22 the convalescent phase of the disease or should predominantly be viewed as an epiphenomenon remains unclear. 23 According to our study, serious cardiac complications are rarely diagnosed during hospitalization with 24 COVID-19, with a prevalence < 2% of patients. To aid interpretation of these numbers it is of interest to relate 25 them to the occurrence of cardiac complications in patients hospitalized for other (viral) infectious diseases. A 26 recent large French retrospective cohort study found that the prevalence of MI and atrial fibrillation was lower 27 in patients with COVID-19 than seasonal influenza with a prevalence of 0.6% vs. 1.1% and 12.4% vs. 15.8% respectively.⁷ Unfortunately, this study did not report the prevalence of any other cardiac complications, 28 including heart failure and myocarditis. As cardiomyocytes express ACE2^{33,34}, the docking receptor of SARS-29 30 CoV-2, it has been speculated that SARS-CoV-2 may infect cardiomyocytes, replicate in cardiac tissue and

1 thereby induce direct myocardial damage. These concerns have also been triggered by the finding that raised 2 levels of troponin above test-specific upper limits are found in up to one third of patients at hospital 3 admission.^{35,36} Histopathological studies of myocardial tissue in the setting of COVID-19 have been scarce up to 4 this point. A literature review evaluating findings of 22 studies across 277 post-mortem examinations, found 5 evidence for myocarditis in <2%.³⁷ This finding contrasts the results of a number of cardiac magnetic resonance 6 (CMR) studies evaluating tissue characteristics and function 2 - 3 months after an established SARS-CoV-2 7 infection.^{32,38-40} In the largest study by Kotecha et al. among 148 patients that had a troponin elevation during 8 hospitalization, non-ischemic myocarditis-like late gadolinium enhancement was found in 26% of patients with 9 one-third showing signs of active myocarditis.³⁹ These findings were not associated with left ventricular 10 dysfunction. In CMR studies conducted predominantly among clinically recovered mildly symptomatic or 11 asymptomatic cases, up to 60% were described to have raised native T2 times, and which the authors suggested 12 might be due to ongoing myocardial inflammation.^{32,40} Whether these CMR findings are unique to patients that 13 have been infected with SARS-CoV-2, or also are seen in other (viral) infectious diseases has been poorly 14 investigated. Evidence of a clear causal relationship between SARS-CoV-2 and myocarditis thereby remains 15 elusive. It can be speculated that most patients may have troponin elevations secondary to profound hypoxia and 16 a supply/demand imbalance rather than direct damage due to viral invasion in cardiac tissue.³⁶ However, the 17 discrepancy in the limited number of patients diagnosed with cardiac complications during hospitalization and 18 the significant proportion of patients with abnormal findings in imaging studies is a concern and warrants 19 further investigation. Cardiac complications may have been missed, due to the overlapping symptomatology 20 with COVID-19 as well as limited access or performed diagnostic tests.

21 Contrary to cardiac complications, which in our study were rarely diagnosed during hospitalization, 22 venous thrombosis and thromboembolism are common features of COVID-19, with a prevalence 3-4 times 23 higher when compared to seasonal influenza.⁷ Thromboembolic events are especially common in patients 24 admitted to the ICU, with pulmonary embolism being diagnosed more than 5 times as often (10.5% vs. 1.4%) in 25 our cohort compared to patients treated on the ward only. The prevalence of pulmonary embolism in the ICU 26 population in our study is lower than in studies based on data originating from patients hospitalized in the first months of the pandemic, that reported a prevalence of up to 20.6%.^{41,42} This discrepancy most likely reflects the 27 28 implementation of enhanced antithrombotic prophylactic strategies in patients admitted with COVID-19 during 2020 and 2021.^{43,44} Interestingly, we observed that thromboembolic complications were less common among 29

1 patients known with cardiac disease in our cohort. This observation is possibly related to pre-admission use of 2 anticoagulants for the treatment of pre-existing cardiac conditions. This will be explored in ongoing analyses.

3 Among different heart disease subtypes, heart failure and especially severe heart failure (NYHA 4 III/IV) was most strongly associated with in-hospital mortality in this study across the spectrum of different 5 heart disease subtypes. Others have also identified patients with heart failure as one of the groups at particular 6 risk.^{45,46} Among 6,439 hospitalized patients, in-hospital mortality was significantly higher among patients with a 7 history of heart failure (aOR 1.88 [95% CI 1.27 – 2.78]).⁴⁵ Similar findings were reported by the Tomasoni et al. 8 (n=692) with a crude HR of 2.43 [95% CI 1.69 - 3.50] for heart failure remaining significant after adjustment 9 for age, sex, various comorbidities and vitals and laboratory values at admission (adjusted HR 2.25 [95% CI 10 1.26 - 4.02].⁴⁶ Whether the absolute risk of being hospitalized in the presence of heart failure is also increased 11 was recently investigated in a population-based study, which found an aOR of 4.43 (95% CI 2.59 - 8.04; p-12 value <0.001).⁴⁷ Besides age and male sex, heart failure had the strongest association with in-hospital mortality 13 among various different comorbidities in this study.

14 Importantly, besides heart failure, none of the other types of heart disease were associated with in-15 hospital mortality after adjustment for age, sex, BMI, diabetes, hypertension, CKD and COPD. This 16 heterogeneity was also evident in the population based study by Petrilli et al. in which patients with CAD did 17 not seem to be at increased risk of hospitalization due to COVID-19 (aOR was 1.08; 95% CI 0.81 - 1.44; p-18 value 0.60).⁴⁷ It could therefore be questioned whether all patients with heart disease should be defined as a 19 group at risk, certainly when viewed in context of other demographic factors such as age and sex, as these 20 appear to contribute to COVID-19 outcome to a much larger extent than pre-existing cardiac disease.¹² This 21 finding is of relevance for clinicians in countries with low vaccination rates and limited critical care capacity, 22 that sometimes are forced to strict prioritization of the initiation and continuation of critical care treatment 23 during this pandemic. Based on the results of this study, a history of cardiac disease, besides severe heart failure, 24 should on itself presumably not be a reason to refrain from critical care treatment.

As heart failure and atrial fibrillation are primarily diseases of the elderly, with a steep increase in the prevalence as well as severity beyond the age of 75 years⁴⁸⁻⁵⁰, a majority of patients with the heart disease subtypes associated with the highest risk as identified in this study are among the first to have been vaccinated according to current vaccine rollout strategies across Europe.²⁷ Adults with comorbidities are identified as an additional priority group but current advice lacks detail on which comorbidities should be considered high-risk. Therefore, we also determined the strength per heart disease subtype and in-hospital mortality in patients <65

years. Due to the lower comorbidity burden in this group, we hypothesized that the associations for the different types of heart disease would be higher in this patient population. However, due to the limited prevalence of heart disease in those aged <65 years of age, we lacked sufficient power to draw any strong conclusions based on this analysis.

5

6 Limitations

7 Our study determines associations on a population level (e.g., all patients with heart failure) rather than 8 individual risks and is limited to patients with COVID-19 that were hospitalized. In some countries that 9 provided data, hospitalization and potentially life-sustaining treatments such as mechanical ventilation, might 10 have been withheld in those with high frailty, including those with severe heart failure, which may have led to 11 an overestimation of the found associations. Conversely, in younger patients treated more intensively, the 12 associations of pre-existing cardiac disease with in-hospital mortality may be underestimated. This 13 heterogeneity may have an impact the found associations. Furthermore, we could not reliably investigate 14 associations between heart disease subtypes and HDU/ICU admission since we observed that patients admitted 15 to a critical care unit were overall younger with fewer comorbidities. Since age in particular is well-known to be 16 associated with a more severe COVID-19 disease course, this difference in baseline characteristics in those 17 admitted to HDU/ICU is suggestive of an underlying selection of patients admitted for critical care. The 18 mechanisms behind this selection are likely complex, influenced by amongst others the variability in critical 19 care bed numbers across participating countries and available staff that may have led to demand for life-saving 20 resources (nearly) exceeding supply, patient preference as well as cultural differences in clinical decision 21 making. A further study limitation is that we only examined the impact of pre-existing cardiac disease on in-22 hospital mortality, which excludes the many deaths that have occurred in community settings and nursing 23 homes. Moreover, there was no central adjudication of events in either of the two registries. Finally, 24 echocardiographic data, providing more in-depth insight into heart failure etiology as well as the degree of 25 systolic and diastolic dysfunction prior to hospitalization are lacking.

26

27 *Future perspectives*

With the approval of several effective vaccines for COVID-19 there is hope of starting the containment of COVID-19 during 2021. During the first year of the pandemic, the scientific community has improved the understanding of this new disease considerably, including its effects on the cardiovascular system. However,

1 many aspects are still unknown. Evidence for a strong causal relationship between SARS-CoV-2 and 2 myocarditis is still lacking. The discrepancy between the low prevalence of clinically diagnosed cardiac 3 complications among the most ill requiring hospitalization and the large proportion of only mildly or even 4 asymptomatic patients with abnormal findings on CMR after the acute phase of the disease has ceased warrant 5 further investigation to understand their specificity and significance. In addition, studies on the long-term 6 incidence of major adverse cardiac events (MACE) are required. Future studies should also evaluate the added 7 value of different pre-existing cardiac comorbidities such as severe heart failure in prognostic models.

8

9 Conclusion

10 In this large retrospective cohort study across sixteen countries, more than one in three patients hospitalized 11 with COVID-19 had underlying chronic cardiac disease. Patients with a history of heart disease were older, 12 more frequently male and had a higher burden of other comorbid conditions at baseline. Inherently, patients 13 with a history of heart disease have a poorer outcome once infected with SARS-CoV-2. However, after 14 multivariable adjustment we did not find a significant association between chronic heart disease and in-hospital 15 mortality. When evaluating the associations between specific heart disease subtypes and in-hospital mortality, 16 considerable heterogeneity was detected. Of all patients with heart disease, those with heart failure are at 17 greatest risk of death when hospitalized with COVID-19. None of the other heart disease subtypes investigated 18 was significantly associated with in-hospital mortality. Furthermore, besides pulmonary embolism, serious 19 cardiovascular complications are rarely diagnosed during hospital admission.

20

21 Funding

This work was supported by the Dutch Heart Foundation (2020B006 CAPACITY), the EuroQol Research Foundation, Novartis Global, Novo Nordisk Nederland, Servier Nederland and Daiichi Sankyo Nederland (CAPACITY-COVID) and the German Centre for Infection Research (DZIF) and the Willy Robert Pitzer Foundation (LEOSS).

Marijke Linschoten is supported by the Alexandre Suerman Stipend of the University Medical Center Utrecht. Folkert W. Asselbergs is supported by CardioVasculair Onderzoek Nederland 2015-12 eDETECT and along with Bryan Williams supported by the NIHR University College London Hospitals Biomedical Research Centre. Fleur V. Y. Tjong is supported by the NWO Rubicon grant 452019308, the Amsterdam Cardiovascular Institute MD/PhD Grant 2019-2020 and Postdoc Grant 2020. The work of Philippe Kopylov and Daria

Gognieva was financed by the Ministry of Science and Higher Education of the Russian Federation within the
 framework of state support for the creation and development of World-Class Research Center Digital biodesign
 and personalized healthcare no. 075-15-2020-926.

4

5 Acknowledgements

6 We want to express our gratitude and appreciation to all participating sites and researchers part of the 7 CAPACITY-COVID collaborative consortium and LEOSS study and all research professionals that have 8 contributed to the data collection. CAPACITY-COVID gratefully acknowledges the following organizations for 9 their assistance in the development of the registry and/or coordination regarding the data registration in the 10 collaborating centers: partners of the Dutch CardioVascular Alliance (DCVA), the Dutch Association of 11 Medical Specialists (FMS) and the British Heart Foundation Centres of Research Excellence. In addition, the 12 consortium is thankful for the endorsement of the CAPACITY-COVID initiative by the European Society of 13 Cardiology (ESC), the European Heart Network (EHN) and the Society for Cardiovascular Magnetic Resonance 14 (SCMR). Furthermore, the consortium appreciates the endorsmenet of CAPACITY-COVD as a flagship 15 research project within the National Institute for Health Research (NIHR)/British Heart Foundation (BHF) 16 Partnership framework for COVID-19 research. Part of this work is supported by the BigData@Heart 17 Consortium, funded by the Innovative Medicines Initiative-2 joint undertaking under grant agreement no 18 116074. This joint undertaking receives support from the EU's Horizon 2020 research and innovation 19 programme and EFPIA. Furthermore we want to thank the LEOSS study infrastructure group: Jörg Janne 20 Vehreschild (Goethe University Frankfurt, University Hospital of Cologne), Lisa Pilgram (Goethe University 21 Frankfurt), Carolin E. M. Jakob (University Hospital of Cologne), Melanie Stecher (University Hospital of 22 Cologne), Max Schons (University Hospital of Cologne), Susana M. Nunes de Miranda (University Hospital of 23 Cologne), Annika Claßen (University Hospital of Cologne), Sandra Fuhrmann (University Hospital of 24 Cologne), Bernd Franke (University Hospital of Cologne), Nick Schulze (University Hospital of Cologne), 25 Fabian Praßer (Charité, Universitätsmedizin Berlin) and Martin Lablans (University Medical Center 26 Mannheim).

27

28 References

29

1. Johns Hopkins Coronavirus Research Center: <u>https://coronavirus.jhu.edu/map.html</u> (4 March 2021).

1	2.	Gudbjartsson DF, Helgason A, Jonsson H, Magnusson OT, Melsted P, Norddahl GL, Saemundsdottir J,
2		Sigurdsson A, Sulem P, Agustsdottir AB, Eiriksdottir B, Fridriksdottir R, Gardarsdottir EE, Georgsson
3		G, Gretarsdottir OS, Gudmundsson KR, Gunnarsdottir TR, Gylfason A, Holm H, Jensson BO,
4		Jonasdottir A, Jonsson F, Josefsdottir KS, Kristjansson T, Magnusdottir DN, le Roux L,
5		Sigmundsdottir G, Sveinbjornsson G, Sveinsdottir KE, Sveinsdottir M, Thorarensen EA,
6		Thorbjornsson B, Löve A, Masson G, Jonsdottir I, Möller AD, Gudnason T, Kristinsson KG,
7		Thorsteinsdottir U, Stefansson K. Spread of SARS-CoV-2 in the Icelandic Population. N Engl J Med.
8		2020;382(24):2302-2315. doi: 10.1056/NEJMoa2006100.
9	3.	Petersen E, Koopmans M, Go U, Hamer DH, Petrosillo N, Castelli F, Storgaard M, Al Khalili S,
10		Simonsen L. Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics. Lancet Infect Dis.
11		2020;20(9):e238-e244. doi: 10.1016/S1473-3099(20)30484-9.
12	4.	WHO Middle East respiratory syndrome coronavirus (MERS-CoV): key facts.
13		https://www.who.int/en/news-room/fact-sheets/detail/middle-east-respiratory-syndrome-coronavirus-
14		(mers-cov) Date: March 11, 2019. (3 September 2020).
15	5.	WHO Update 49—SARS case fatality ratio, incubation period.
16		https://www.who.int/csr/sars/archive/2003_05_07a/en/ Date: May 7, 2003. (3 September 2020).
16 17	6.	https://www.who.int/csr/sars/archive/2003_05_07a/en/ Date: May 7, 2003. (3 September 2020). Ruan S. Likelihood of survival of coronavirus disease 2019. Lancet Infect Dis. 2020;20(6):630-631.
	6.	
17	6. 7.	Ruan S. Likelihood of survival of coronavirus disease 2019. Lancet Infect Dis. 2020;20(6):630-631.
17 18		Ruan S. Likelihood of survival of coronavirus disease 2019. Lancet Infect Dis. 2020;20(6):630-631. doi: 10.1016/S1473-3099(20)30257-7.
17 18 19		Ruan S. Likelihood of survival of coronavirus disease 2019. Lancet Infect Dis. 2020;20(6):630-631. doi: 10.1016/S1473-3099(20)30257-7. Piroth L, Cottenet J, Mariet AS, Bonniaud P, Blot M, Tubert-Bitter P, Quantin C. Comparison of the
17 18 19 20		Ruan S. Likelihood of survival of coronavirus disease 2019. Lancet Infect Dis. 2020;20(6):630-631. doi: 10.1016/S1473-3099(20)30257-7. Piroth L, Cottenet J, Mariet AS, Bonniaud P, Blot M, Tubert-Bitter P, Quantin C. Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide,
17 18 19 20 21		Ruan S. Likelihood of survival of coronavirus disease 2019. Lancet Infect Dis. 2020;20(6):630-631. doi: 10.1016/S1473-3099(20)30257-7. Piroth L, Cottenet J, Mariet AS, Bonniaud P, Blot M, Tubert-Bitter P, Quantin C. Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study. Lancet Respir Med. 2020;9(3):251–9. doi:
17 18 19 20 21 22	7.	Ruan S. Likelihood of survival of coronavirus disease 2019. Lancet Infect Dis. 2020;20(6):630-631. doi: 10.1016/S1473-3099(20)30257-7. Piroth L, Cottenet J, Mariet AS, Bonniaud P, Blot M, Tubert-Bitter P, Quantin C. Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study. Lancet Respir Med. 2020;9(3):251–9. doi: 10.1016/S2213-2600(20)30527-0.
 17 18 19 20 21 22 23 	7.	 Ruan S. Likelihood of survival of coronavirus disease 2019. Lancet Infect Dis. 2020;20(6):630-631. doi: 10.1016/S1473-3099(20)30257-7. Piroth L, Cottenet J, Mariet AS, Bonniaud P, Blot M, Tubert-Bitter P, Quantin C. Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study. Lancet Respir Med. 2020;9(3):251–9. doi: 10.1016/S2213-2600(20)30527-0. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, Holden KA, Read JM,
 17 18 19 20 21 22 23 24 	7.	 Ruan S. Likelihood of survival of coronavirus disease 2019. Lancet Infect Dis. 2020;20(6):630-631. doi: 10.1016/S1473-3099(20)30257-7. Piroth L, Cottenet J, Mariet AS, Bonniaud P, Blot M, Tubert-Bitter P, Quantin C. Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study. Lancet Respir Med. 2020;9(3):251–9. doi: 10.1016/S2213-2600(20)30527-0. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, Holden KA, Read JM, Dondelinger F, Carson G, Merson L, Lee J, Plotkin D, Sigfrid L, Halpin S, Jackson C, Gamble C,
 17 18 19 20 21 22 23 24 25 	7.	 Ruan S. Likelihood of survival of coronavirus disease 2019. Lancet Infect Dis. 2020;20(6):630-631. doi: 10.1016/S1473-3099(20)30257-7. Piroth L, Cottenet J, Mariet AS, Bonniaud P, Blot M, Tubert-Bitter P, Quantin C. Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study. Lancet Respir Med. 2020;9(3):251–9. doi: 10.1016/S2213-2600(20)30527-0. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, Holden KA, Read JM, Dondelinger F, Carson G, Merson L, Lee J, Plotkin D, Sigfrid L, Halpin S, Jackson C, Gamble C, Horby PW, Nguyen-Van-Tam JS, Ho A, Russell CD, Dunning J, Openshaw PJ, Baillie JK, Semple
 17 18 19 20 21 22 23 24 25 26 	7.	Ruan S. Likelihood of survival of coronavirus disease 2019. Lancet Infect Dis. 2020;20(6):630-631. doi: 10.1016/S1473-3099(20)30257-7. Piroth L, Cottenet J, Mariet AS, Bonniaud P, Blot M, Tubert-Bitter P, Quantin C. Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study. Lancet Respir Med. 2020;9(3):251–9. doi: 10.1016/S2213-2600(20)30527-0. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, Holden KA, Read JM, Dondelinger F, Carson G, Merson L, Lee J, Plotkin D, Sigfrid L, Halpin S, Jackson C, Gamble C, Horby PW, Nguyen-Van-Tam JS, Ho A, Russell CD, Dunning J, Openshaw PJ, Baillie JK, Semple MG; ISARIC4C investigators. Features of 20 \Box 133 UK patients in hospital with covid-19 using the
 17 18 19 20 21 22 23 24 25 26 27 	7.	Ruan S. Likelihood of survival of coronavirus disease 2019. Lancet Infect Dis. 2020;20(6):630-631. doi: 10.1016/S1473-3099(20)30257-7. Piroth L, Cottenet J, Mariet AS, Bonniaud P, Blot M, Tubert-Bitter P, Quantin C. Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study. Lancet Respir Med. 2020;9(3):251–9. doi: 10.1016/S2213-2600(20)30527-0. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, Holden KA, Read JM, Dondelinger F, Carson G, Merson L, Lee J, Plotkin D, Sigfrid L, Halpin S, Jackson C, Gamble C, Horby PW, Nguyen-Van-Tam JS, Ho A, Russell CD, Dunning J, Openshaw PJ, Baillie JK, Semple MG; ISARIC4C investigators. Features of 20□133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ.

1		Cardiac complications in patients hospitalised with COVID-19. Eur Heart J Acute Cardiovasc Care.
2		2020;9(8):817-823. doi: 10.1177/2048872620974605.
3	10.	Yehia BR, Winegar A, Fogel R, Fakih M, Ottenbacher A, Jesser C, Bufalino A, Huang RH, Cacchione
4		J. Association of Race With Mortality Among Patients Hospitalized With Coronavirus Disease 2019
5		(COVID-19) at 92 US Hospitals. JAMA Netw Open. 2020;3(8):e2018039. doi:
6		10.1001/jamanetworkopen.2020.18039.
7	11.	Fried MW, Crawford JM, Mospan AR, Watkins SE, Munoz Hernandez B, Zink RC, Elliott S, Burleson
8		K, Landis C, Reddy KR, Brown RS. Patient Characteristics and Outcomes of 11,721 Patients with
9		COVID19 Hospitalized Across the United States. Clin Infect Dis. 2020:ciaa1268. doi:
10		10.1093/cid/ciaa1268. Epub ahead of print.
11	12.	Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, Curtis HJ, Mehrkar A, Evans
12		D, Inglesby P, Cockburn J, McDonald HI, MacKenna B, Tomlinson L, Douglas IJ, Rentsch CT,
13		Mathur R, Wong AYS, Grieve R, Harrison D, Forbes H, Schultze A, Croker R, Parry J, Hester F,
14		Harper S, Perera R, Evans SJW, Smeeth L, Goldacre B. Factors associated with COVID-19-related
15		death using OpenSAFELY. Nature. 2020;584(7821):430-436. doi: 10.1038/s41586-020-2521-4.
16	13.	Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019
17		(COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for
18		Disease Control and Prevention. JAMA. 2020;323(13):1239-1242. doi: 10.1001/jama.2020.2648.
19	14.	Weng TC, Chiu HR, Chen SY, Shih FY, King CC, Fang CC. National retrospective cohort study to
20		identify age-specific fatality risks of comorbidities among hospitalised patients with influenza-like
21		illness in Taiwan. BMJ Open. 2019;9(6):e025276. doi: 10.1136/bmjopen-2018-025276.
22	15.	Mertz D, Kim TH, Johnstone J, Lam PP, Science M, Kuster SP, Fadel SA, Tran D, Fernandez E,
23		Bhatnagar N, Loeb M. Populations at risk for severe or complicated influenza illness: systematic
24		review and meta-analysis. BMJ. 2013;347:f5061. doi: 10.1136/bmj.f5061.
25	16.	Siropaides CH, Sulistio MS, Reimold SC. Crucial Conversations With Patients in the Era of COVID-
26		19. Circulation. 2020;142(3):191-193. doi: 10.1161/CIRCULATIONAHA.120.047374. Epub 2020
27		May 6.
28	17.	Mafham MM, Spata E, Goldacre R, Gair D, Curnow P, Bray M, Hollings S, Roebuck C, Gale CP,
29		Mamas MA, Deanfield JE, de Belder MA, Luescher TF, Denwood T, Landray MJ, Emberson JR,
30		Collins R, Morris EJA, Casadei B, Baigent C. COVID-19 pandemic and admission rates for and

1	management of acute coronary syndromes in England. Lancet. 2020;396(10248):381-389. doi
2	10.1016/S0140-6736(20)31356-8.
3	18. Linschoten M, Asselbergs FW. CAPACITY-COVID: a European Registry to determine the role of
4	cardiovascular disease in the COVID-19 pandemic. Eur Heart J. 2020;41(19):1795-1796. doi
5	10.1093/eurheartj/ehaa280.
6	19. ISARIC COVID-19 CRF. https://isaric.org/research/covid-19-clinical-research-resources/covid-19-crf/
7	(16 of February 2021).
8	20. Caforio AL, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB, Fu M, Heliö T, Heyman
9	S, Jahns R, Klingel K, Linhart A, Maisch B, McKenna W, Mogensen J, Pinto YM, Ristic A
10	Schultheiss HP, Seggewiss H, Tavazzi L, Thiene G, Yilmaz A, Charron P, Elliott PM; Europear
11	Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Current state of
12	knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of
13	the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eu
14	Heart J. 2013;34(33):2636-48, 2648a-2648d. doi: 10.1093/eurheartj/eht210.
15	21. Adler Y, Charron P, Imazio M, Badano L, Barón-Esquivias G, Bogaert J, Brucato A, Gueret P, Klinge
16	K, Lionis C, Maisch B, Mayosi B, Pavie A, Ristic AD, Sabaté Tenas M, Seferovic P, Swedberg K
17	Tomkowski W; ESC Scientific Document Group. 2015 ESC Guidelines for the diagnosis and
18	management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardia
19	Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for
20	Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2015;36(42):2921-2964. doi
21	10.1093/eurheartj/ehv318.
22	22. Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta JP, Del Zotti F, Dulgheru R, El Khoury
23	G, Erba PA, Iung B, Miro JM, Mulder BJ, Plonska-Gosciniak E, Price S, Roos-Hesselink J, Snygg
24	Martin U, Thuny F, Tornos Mas P, Vilacosta I, Zamorano JL; ESC Scientific Document Group. 2015
25	ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of
26	Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European
27	Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine
28	(EANM). Eur Heart J. 2015;36(44):3075-3128. doi: 10.1093/eurheartj/ehv319.
29	23. Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, Bax JJ, Borger MA, Brotons C
30	Chew DP, Gencer B, Hasenfuss G, Kjeldsen K, Lancellotti P, Landmesser U, Mehilli J, Mukherjee D

Storey RF, Windecker S; ESC Scientific Document Group. 2015 ESC Guidelines for the management
 of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task
 Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(3):267-315.
 doi: 10.1093/eurheartj/ehv320.

6 24. Buxton AE, Calkins H, Callans DJ, DiMarco JP, Fisher JD, Greene HL, Haines DE, Hayes DL, 7 Heidenreich PA, Miller JM, Poppas A, Prystowsky EN, Schoenfeld MH, Zimetbaum PJ, Heidenreich 8 PA, Goff DC, Grover FL, Malenka DJ, Peterson ED, Radford MJ, Redberg RF; American College of 9 Cardiology; American Heart Association Task Force on Clinical Data Standards; (ACC/AHA/HRS 10 Writing Committee to Develop Data Standards on Electrophysiology). ACC/AHA/HRS 2006 key data 11 elements and definitions for electrophysiological studies and procedures: a report of the American 12 College of Cardiology/American Heart Association Task Force on Clinical Data Standards 13 (ACC/AHA/HRS Writing Committee to Develop Data Standards on Electrophysiology). J Am Coll 14 Cardiol. 2006;48(11):2360-96. doi: 10.1016/j.jacc.2006.09.020.

- 15 25. Jakob CEM, Borgmann S, Duygu F, Behrends U, Hower M, Merle U, Friedrichs A, Tometten L,
 16 Hanses F, Jung N, Rieg S, Wille K, Grüner B, Klinker H, Gersbacher-Runge N, Hellwig K, Eberwein
 17 L, Dolff S, Rauschning D, von Bergwelt-Baildon M, Lanznaster J, Strauß R, Trauth J, de With K,
 18 Ruethrich M, Lueck C, Nattermann J, Tscharntke L, Pilgram L, Fuhrmann S, Classen A, Stecher M,
 19 Schons M, Spinner C, Vehreschild JJ. First results of the "Lean European Open Survey on SARS-CoV20 2-Infected Patients (LEOSS)". Infection. 2021 Feb;49(1):63-73. doi: 10.1007/s15010-020-01499-0.
- 26. Jakob CEM, Kohlmayer F, Meurers T, Vehreschild JJ, Prasser F. Design and evaluation of a data
 anonymization pipeline to promote Open Science on COVID-19. Sci Data. 2020 Dec 10;7(1):435. doi:
 10.1038/s41597-020-00773-y.
- 24 27. European Centre for Disease Prevention and Control. Overview of COVID-19 vaccination strategies
 25 and vaccine deployment plans in the EU/EEA and the UK 2 December 2020. ECDC: Stockholm;
 26 2020.
- 27 28. Pritchard MG, ISARIC Clinical Characterisation Group. COVID-19 symptoms at hospital admission
 28 vary with age and sex: ISARIC multinational study.
- 29 medRxiv 2020.10.26.20219519; doi:https://doi.org/10.1101/2020.10.26.20219519

1	29. Michelen M, Manoharan L, Elkheir N, Cheng V, Dagens D, Hastie C, O'Hara M, Suet JC, Burls A
2	Foote C, Carson G, Olliaro P, Sigfrid L, Stavropoulou C. Characterising long-term covid-19: a rapi
3	living systematic review.
4	medRxiv 2020.12.08.20246025; doi:https://doi.org/10.1101/2020.12.08.20246025
5	30. Carfì A, Bernabei R, Landi F; Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent
6	Symptoms in Patients After Acute COVID-19. JAMA. 2020;324(6):603-605. doi:
7	10.1001/jama.2020.12603.
8	31. Goërtz YMJ, Van Herck M, Delbressine JM, Vaes AW, Meys R, Machado FVC, Houben-Wilke S
9	Burtin C, Posthuma R, Franssen FME, van Loon N, Hajian B, Spies Y, Vijlbrief H, van 't Hul A.
10	Janssen DJA, Spruit MA. Persistent symptoms 3 months after a SARS-CoV-2 infection: the post
11	COVID-19 syndrome? ERJ Open Res. 2020;6(4):00542-2020. doi: 10.1183/23120541.00542-2020.
12	32. Puntmann VO, Carerj ML, Wieters I, Fahim M, Arendt C, Hoffmann J, Shchendrygina A, Escher H
13	Vasa-Nicotera M, Zeiher AM, Vehreschild M, Nagel E. Outcomes of Cardiovascular Magneti
14	Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19
15	JAMA Cardiol. 2020;5(11):1265-1273. doi: 10.1001/jamacardio.2020.3557. Erratum in: JAMA
16	Cardiol. 2020;5(11):1308.
17	33. Nicin L, Abplanalp WT, Mellentin H, Kattih B, Tombor L, John D, Schmitto JD, Heineke J, Emrich H
18	Arsalan M, Holubec T, Walther T, Zeiher AM, Dimmeler S. Cell type-specific expression of th
19	putative SARS-CoV-2 receptor ACE2 in human hearts. Eur Heart J. 2020;41(19):1804-1806. do
20	10.1093/eurheartj/ehaa311.
21	34. The Human Protein Atlas: <u>https://www.proteinatlas.org/ENSG00000130234-ACE2/celltype</u> (2
22	February 2021)
23	35. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW; the Northwe
24	COVID-19 Research Consortium, Barnaby DP, Becker LB, Chelico JD, Cohen SL, Cookingham
25	Coppa K, Diefenbach MA, Dominello AJ, Duer-Hefele J, Falzon L, Gitlin J, Hajizadeh N, Harvin TC
26	Hirschwerk DA, Kim EJ, Kozel ZM, Marrast LM, Mogavero JN, Osorio GA, Qiu M, Zanos TF
27	Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized Wit
28	COVID-19 in the New York City Area. JAMA. 2020;323(20):2052-2059. do
29	10.1001/jama.2020.6775. Erratum in: JAMA. 2020;323(20):2098.

1	36.	Lala A, Johnson KW, Januzzi JL, Russak AJ, Paranjpe I, Richter F, Zhao S, Somani S, Van Vleck T,
2		Vaid A, Chaudhry F, De Freitas JK, Fayad ZA, Pinney SP, Levin M, Charney A, Bagiella E, Narula J,
3		Glicksberg BS, Nadkarni G, Mancini DM, Fuster V; Mount Sinai COVID Informatics Center.
4		Prevalence and Impact of Myocardial Injury in Patients Hospitalized With COVID-19 Infection. J Am
5		Coll Cardiol. 2020 Aug 4;76(5):533-546. doi: 10.1016/j.jacc.2020.06.007. Epub 2020 Jun 8.
б	37.	Halushka MK, Vander Heide RS. Myocarditis is rare in COVID-19 autopsies: cardiovascular findings
7		across 277 postmortem examinations. Cardiovasc Pathol. 2021;50:107300. doi:
8		10.1016/j.carpath.2020.107300.
9	38.	Huang L, Zhao P, Tang D, Zhu T, Han R, Zhan C, Liu W, Zeng H, Tao Q, Xia L. Cardiac Involvement
10		in Patients Recovered From COVID-2019 Identified Using Magnetic Resonance Imaging. JACC
11		Cardiovasc Imaging. 2020;13(11):2330-2339. doi: 10.1016/j.jcmg.2020.05.004.
12	39.	Kotecha T, Knight DS, Razvi Y, Kumar K, Vimalesvaran K, Thornton G, Patel R, Chacko L, Brown
13		JT, Coyle C, Leith D, Shetye A, Ariff B, Bell R, Captur G, Coleman M, Goldring J, Gopalan D,
14		Heightman M, Hillman T, Howard L, Jacobs M, Jeetley PS, Kanagaratnam P, Kon OM, Lamb LE,
15		Manisty CH, Mathurdas P, Mayet J, Negus R, Patel N, Pierce I, Russell G, Wolff A, Xue H, Kellman
16		P, Moon JC, Treibel TA, Cole GD, Fontana M. Patterns of myocardial injury in recovered troponin-
17		positive COVID-19 patients assessed by cardiovascular magnetic resonance. Eur Heart J.
18		2021:ehab075. doi: 10.1093/eurheartj/ehab075. Epub ahead of print.
19	40.	Rajpal S, Tong MS, Borchers J, Zareba KM, Obarski TP, Simonetti OP, Daniels CJ. Cardiovascular
20		Magnetic Resonance Findings in Competitive Athletes Recovering From COVID-19 Infection. JAMA
21		Cardiol. 2021;6(1):116-118. doi: 10.1001/jamacardio.2020.4916.
22	41.	Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, Kaptein FHJ,
23		van Paassen J, Stals MAM, Huisman MV, Endeman H. Incidence of thrombotic complications in
24		critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145-147. doi:
25		10.1016/j.thromres.2020.04.013.
26	42.	Poissy J, Goutay J, Caplan M, Parmentier E, Duburcq T, Lassalle F, Jeanpierre E, Rauch A, Labreuche
27		J, Susen S; Lille ICU Haemostasis COVID-19 Group. Pulmonary Embolism in Patients With COVID-
28		19: Awareness of an Increased Prevalence. Circulation. 2020;142(2):184-186. doi:
29		10.1161/CIRCULATIONAHA.120.047430.

21

1 43. Angchaisuksiri P, Blair C, Dane K, Davila J, DeSancho MT, Diuguid D, Griffin DO, Kahn SR, Klok 2 FA, Lee AI, Neumann I, Pai A, Pai M, Righini M, Sanfilippo KM, Siegal D, Skara M, Touri K, Akl 3 EA, Bou Akl I, Boulos M, Brignardello-Petersen R, Charide R, Chan M, Dearness K, Darzi AJ, Kolb 4 P, Colunga-Lozano LE, Mansour R, Morgano GP, Morsi RZ, Noori A, Piggott T, Qiu Y, Roldan Y, 5 Schünemann F, Stevens A, Solo K, Ventresca M, Wiercioch W, Mustafa RA, Schünemann HJ. 6 American Society of Hematology 2021 guidelines on the use of anticoagulation for 7 thromboprophylaxis in patients with COVID-19. Blood Adv. 2021 Feb 9;5(3):872-888. doi: 8 10.1182/bloodadvances.2020003763. 9 44. Chalmers JD, Crichton ML, Goeminne PC, Cao B, Humbert M, Shteinberg M, Antoniou KM, Ulrik 10 CS, Parks H, Wang C, Vandendriessche T, Qu J, Stolz D, Brightling C, Welte T, Aliberti S, Simonds 11 AK, Tonia T, Roche N. Management of hospitalised adults with coronavirus disease 2019 (COVID-12 19): a European Respiratory Society living guideline. Eur Respir J. 2021 Apr 15;57(4):2100048. doi: 13 10.1183/13993003.00048-2021. 14 45. Alvarez-Garcia J, Lee S, Gupta A, Cagliostro M, Joshi AA, Rivas-Lasarte M, Contreras J, Mitter SS, 15 LaRocca G, Tlachi P, Brunjes D, Glicksberg BS, Levin MA, Nadkarni G, Fayad Z, Fuster V, Mancini 16 D, Lala A. Prognostic Impact of Prior Heart Failure in Patients Hospitalized With COVID-19. J Am 17 Coll Cardiol. 2020 Nov 17;76(20):2334-2348. doi: 10.1016/j.jacc.2020.09.549. 18 46. Tomasoni D, Inciardi RM, Lombardi CM, Tedino C, Agostoni P, Ameri P, Barbieri L, Bellasi A, 19 Camporotondo R, Canale C, Carubelli V, Carugo S, Catagnano F, Dalla Vecchia LA, Danzi GB, Di 20 Pasquale M, Gaudenzi M, Giovinazzo S, Gnecchi M, Iorio A, La Rovere MT, Leonardi S, Maccagni G, 21 Mapelli M, Margonato D, Merlo M, Monzo L, Mortara A, Nuzzi V, Piepoli M, Porto I, Pozzi A, 22 Sarullo F, Sinagra G, Volterrani M, Zaccone G, Guazzi M, Senni M, Metra M. Impact of heart failure 23 on the clinical course and outcomes of patients hospitalized for COVID-19. Results of the Cardio-24 COVID-Italy multicentre study. Eur J Heart Fail. 2020;22(12):2238-2247. doi: 10.1002/ejhf.2052. 25 47. Petrilli CM, Jones SA, Yang J, Rajagopalan H, O'Donnell L, Chernyak Y, Tobin KA, Cerfolio RJ, 26 Francois F, Horwitz LI. Factors associated with hospital admission and critical illness among 5279 27 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 28 2020;369:m1966. doi: 10.1136/bmj.m1966.

22

1	48. Störk S, Handrock R, Jacob J, Walker J, Calado F, Lahoz R, Hupfer S, Klebs S. Epidemiology of heart
2	failure in Germany: a retrospective database study. Clin Res Cardiol. 2017;106(11):913-922. doi:
3	10.1007/s00392-017-1137-7.
4	49. Ammar KA, Jacobsen SJ, Mahoney DW, Kors JA, Redfield MM, Burnett JC Jr, Rodeheffer RJ.
5	Prevalence and prognostic significance of heart failure stages: application of the American College of
6	Cardiology/American Heart Association heart failure staging criteria in the community. Circulation.
7	2007;115(12):1563-70. doi: 10.1161/CIRCULATIONAHA.106.666818.
8	50. Schnabel RB, Yin X, Gona P, Larson MG, Beiser AS, McManus DD, Newton-Cheh C, Lubitz SA,
9	Magnani JW, Ellinor PT, Seshadri S, Wolf PA, Vasan RS, Benjamin EJ, Levy D. 50 year trends in
10	atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a
11	cohort study. Lancet. 2015 Jul 11;386(9989):154-62. doi: 10.1016/S0140-6736(14)61774-8.
12	
13	Figure legends
14	Figure 1: Associations (crude: top; age- and sex adjusted; center, multivariable adjusted; bottom) between any
15	history of cardiac disease, heart disease subtypes and in-hospital mortality. P-values are adjusted for multiple
16	testing.
17	
18	Figure 2: Multivariable adjusted associations between any history of cardiac disease, heart disease subtypes and
19	in-hospital mortality in patients aged <65 (top) and >65 years (bottom). *p-value interaction heart disease
20	subtype and age. Patients with prior myocardial infarction are included in the coronary artery disease group.
21	
22	Disclosures
23	See disclosure paragraph.
24	
25	
26	
27	
28	
29	
30	
31	
32	

- 17 Figure
- 18 Figure 1

In-hospital mortality


RR (95% CI) p-value* Crude Any history of cardiac disease < 0.01 [1.76 - 1.99 1.87 1.87 | 1.70 - 1.99 1.73 | 1.62 - 1.85 1.73 | 1.61 - 1.86 1.68 | 1.57 - 1.80 1.55 | 1.39 - 1.74 1.99 | 1.84 - 2.15 1.72 | 1.47 - 2.02 2.37 | 2.06 - 2.74 1.68 | 4.09 - 1.80 <0.01 <0.01 <0.01 <0.01 Arrhythmia/conduction disorder Atrial fibrillation Coronary artery disease Myocardial infarction < 0.01 Heart failure < 0.01 NYHA I/II NYHA III/IV <0.01 <0.01 1.68 [1.49 - 1.89] Valvular disease <0.01 Age and sex adjusted Any history of cardiac disease Arrhythmia/conduction disorder < 0.018 H 1.13 [1.06 - 1.20] 0.99 - 1.13 0.72 1.06 1.07 -Atrial fibrillation 1.07 11.00 - 1.15 1.14 1.06 - 1.22 1.10 (0.99 - 1.22) 1.31 (1.21 - 1.42) 1.16 (0.98 - 1.36) 1.53 (1.32 - 1.78) 1.11 (0.98 - 1.25) <0.70 <0.018 0.72 <0.018 0.72 Coronary artery disease Myocardial infarction Heart failure NYHA I/II NYHA III/IV < 0.018 Valvular disease 0.72 Multivariable adjusted Any history of cardiac disease Arrhythmia/conduction disorder $\begin{bmatrix} 1.02 - 1.15 \\ 0.94 - 1.08 \\ 0.97 - 1.12 \\ 1.03 - 1.18 \\ 0.96 - 1.19 \\ 0.96 - 1.29 \end{bmatrix}$ 1.08 1.01 1.04 0.12 1.00 1.00 Atrial fibrillation Coronary artery disease Myocardial infarction Heart failure NYHA I/II NYHA III/IV 1.10 1.07 1.00 1.10 - 1.30 0.90 - 1.24 1.20 - 1.64 1.19 < 0.018 1.00 1.05 1.41 < 0.018 1.03 0.91 - 1.16 1.00 Valvular disease 0.75 1.0 1.5 2.0 3.0 RR (log-scale)

1

1 Figure 2

ue

In-hospital mortality



1 Authors

2 Linschoten M¹, Uijl A², Schut A³, Jakob CEM^{4,5}, Romão LR^{6,7}, Bell RM⁸, McFarlane E⁹, Stecher M^{4,5}, Zondag AGM², van Iperen EPA¹⁰, Hermans-van Ast W¹⁰, Lea NC⁷, Schaap J^{3,11}, Jewbali LS^{12,13}, Smits PC¹⁴, Patel RS^{7,9}, 3 Aujayeb A¹⁵, Ripley DP¹⁶, Saxena M¹⁷, Spinner C^{5,18}, McCann GP¹⁹, Moss AJ¹⁹, Parker E¹⁹, Borgmann S²⁰. 4 Tessitore E²¹, Rieg S²², Kearnev MT²³, Byrom-Goulthorp R²³, Hower M²⁴, Al-Ali AK²⁵, Alshehri AM²⁶, Alnafie 5 AN²⁷. Alshahrani M²⁸. Almubarak YA²⁹, Al-Muhanna FA³⁰, Al-Rubaish AM³⁰, Hanses F³¹, Shore AC³², Ball 6 C³², Anning CM³², Rüthrich MM³³, Nierop PR³⁴, Vehreschild MJGT³⁵, Heymans SRB³⁶⁻³⁸, Henkens MTHM³⁶, 7 Raafs AG³⁶, van der Horst ICC³⁹, van Bussel BCT³⁹, Magdelijns FJH⁴⁰, Lanznaster J⁴¹, Kopylov PY⁴², Blagova 8 OV⁴³, Wille K⁴⁴, Pinto YM⁴⁵, Offerhaus JA⁴⁵, Bleijendaal H^{45,46}, Piepel C⁴⁷, ten Berg JM⁴⁸, Bor WL⁴⁸, Maarse 9 M⁴⁸, Römmele C⁴⁹, Tio RA^{50,51}, Sturkenboom NH⁵⁰, Tometten L⁵², den Uil CA^{12,13}, Scholte NTB¹², Groenendijk 10 AL⁵³, Dolff S⁵⁴, Zijlstra LE⁵⁵, Hilt AD⁵⁵, von Bergwelt-Baildon M⁵⁶⁻⁵⁸, Groenemeijer BE⁵⁹, Merle U⁶⁰, van der 11 Zee PM⁶¹, van Beek EA⁶¹, Rothfuss K⁶², Tjong FVY^{45, 63,64}, van der Lingen ACJ⁶³, Kolk MZH⁴⁵, Isberner N⁶⁵, 12 Monraats PS⁶⁶, Magro M⁶⁶, Hermans WRM⁶⁶, Kochanek M^{67,68}, Captur G^{9,69}, Thomson RJ^{70,71}, Nadalin S⁷², 13 Linssen GCM⁷³, Veneman T⁷⁴, Zaal R⁷⁵, Degenhardt C⁷⁶, Martens FMAC⁷⁷, Badings EA⁷⁷, Strauss R⁷⁸, Zaman 14 AG⁷⁹, Alkhalil M⁸⁰, Prasad S^{81,82}, Grüner B⁸³, Haerkens-Arends HE⁸⁴, Eberwein L⁸⁵, Dark P⁸⁶, Lomas D⁸⁶, vom 15 Dahl J⁸⁷, Verschure DO⁸⁸, Hellwig K⁸⁹, Mosterd A⁹⁰, Rauschning D⁹¹, van der Heijden DJ⁹², Neufang M⁹³, van 16 Hessen M⁹⁴, Raichle C⁹⁵, Montagna L⁹⁶, Mazzilli SG⁹⁷, Bianco M⁹⁸, Westhoff T⁹⁹, Shafiee A¹⁰⁰, Hedayat B¹⁰¹, 17 Saneei E¹⁰², Porhosseini H¹⁰³, Jensen B¹⁰⁴, Gabriel L¹⁰⁵, Er AG¹⁰⁶, Kietselaer BLJH¹⁰⁷, Schubert J¹⁰⁸, 18 Timmermans P Jr¹⁰⁹, Messiaen P^{110,111}, Friedrichs A¹¹², van den Brink FS¹¹³, Woudstra P¹¹³, Trauth J¹¹⁴, Ribeiro 19 MIA¹¹⁵, de With K¹¹⁶, van der Linden MMJM¹¹⁷, Kielstein JT¹¹⁸, Macías Ruiz R¹¹⁹, Guggemos W¹²⁰, Hellou 20 E¹²¹, Markart P¹²², van Kesteren HAM¹²³, Heigener D¹²⁴, de Vries JK¹²⁵, Stieglitz S¹²⁶, Baltazar JB¹²⁷, Voigt I¹²⁸, 21 van de Watering DJ¹²⁹, Milovanovic M¹³⁰, Redón J^{131,132}, Forner MJ^{131,132}, Rüddel J¹³³, Wu KW¹³⁴, Nattermann 22 J¹³⁵, Veldhuis LI¹³⁶, Westendorp ICD¹³⁷, Riedel C¹³⁸, Kwakkel-van Erp JM¹³⁹, van Ierssel S¹⁴⁰, van 23 Craenenbroeck EM¹⁴¹, Walter L¹⁴², de Sutter J^{143,144}, Worm M¹⁴⁵, Drost JT¹⁴⁶, Moriarty A¹⁴⁷, Salah R¹⁴⁸, 24 Charlotte N¹⁴⁹, van Boxem AJM¹⁵⁰, Dorman HGR¹⁵¹, Reidinga AC¹⁵², van der Meer P¹⁵³, Wierda E⁶⁴, van Veen 25 HPAA¹⁵⁴, Delsing CE¹⁵⁵, Meijs MFL¹⁵⁶, van de Wal RMA¹⁵⁷, Weytjens C¹⁵⁸, Hermanides RS¹⁵⁹, Emans ME¹⁶⁰, 26 al-Windy NYY¹⁶¹, Koning AMH¹⁶², Schellings DAAM¹⁶³, Anthonio RL¹⁶⁴, Bucciarelli- Ducci C¹⁶⁵, Caputo 27 M^{166,167}, Westendorp PHM¹⁶⁸, Kuijper AFM¹⁶⁹, van Ofwegen-Hanekamp CEE¹⁷⁰, Persoon AM¹⁷¹, Seelig J¹⁷², 28 van der Harst P¹, Siebelink HJ⁵⁵, van Smeden M², Williams S¹⁷³, Pilgram L¹⁷⁴, van Gilst WH¹⁷⁵, Tieleman 29 30 RG¹⁷⁶, Williams B^{6,9}, Asselbergs FW^{1,7,9}.

31

32 Collaborators

Alling TE¹, Ahmed R¹⁵, Handgraaf S²¹, Gognieva DG⁴², Mesitskaya DF¹⁷⁷, van der Graaf M¹², Ruiter AH¹². 33 Pölkerman BC⁵⁹, Jansen SE⁵⁹, Selder JL^{45,63}, Pieterse-Rots A⁷³, Kuipers-Elferink L⁷³, van der Sluis A⁷⁷, van Eck 34 35 JWM⁸⁴, Gevers RMM⁸⁴, van Dalen DH⁸⁴, Lensink E⁸⁸, Bunschoten P⁹⁰, van Doorn JL⁹⁰, Knufman N⁹², van Marrewijk V⁹², Broekman M⁹⁴, Bos M⁹⁴, Perrelli MG⁹⁶, Biolé CA⁹⁶, Hosseini K¹⁰¹, Tajdini M¹⁷⁸, Domange 36 JD¹⁰⁵, Dormal FD¹⁰⁵, Jourdan JD¹⁰⁵, Kleikers P¹⁰⁷, Hessels-Linnemeijer BM¹⁰⁷, Dekimpe E¹⁰⁹, Janssen A¹⁰⁹, 37 38 Sousa AIC¹¹⁵, Cardoso NM¹¹⁵, Tercedor Sánchez L¹¹⁹, Bermúdez Jiménes J¹¹⁹, Koole BAS¹²³, Huisman J¹²³, Kui KK¹²⁵, Bruinsma S¹²⁵, Kievit CM¹³⁴, van Kempen MJ¹³⁴, Melein AJ¹³⁷, Koole MAC¹³⁷, van Poppel A¹³⁹, van 39 Meerbeeck JP¹³⁹, Vlieghe E¹⁴⁰, ten Kate GL¹⁴⁰, Heidbuchel H¹⁴¹, van de Heyning CM¹⁴¹, Willems AM¹⁴³, Meijer 40

- 1 EJ¹⁴⁶, Habib A¹⁷⁹, Elshinawy K¹⁷⁹, Vial H¹⁸⁰, Grangeon S¹⁸⁰, Wils AM¹⁵¹, Jacobs TC¹⁵¹, Vreugdenhil P¹⁷⁶,
- 2 Hendriks-van Woerden M¹⁷⁶, van Aken K¹⁵³, Hamilton K¹⁵³, van Nes CPM⁶⁴, Vonkeman HE¹⁸¹, Haenen NA¹⁵⁷,
- 3 de Bruijn EAW¹⁸², Cosyns B¹⁵⁸, Lemoine I¹⁵⁸, Guclu A¹⁵⁹, Dunnink A¹⁵⁹, den Boer-Penning P¹⁶⁰, Zoet-Nugteren
- 4 SK¹⁶⁰, Reitsma MJ¹⁶², Broeyer FJF¹⁸³, Drost IMJ¹⁶³, Reinders S¹⁶³, van der Kooi SE¹⁶⁴, Paris FMA¹⁶⁴,
- 5 Bayraktar-Verver ECE¹⁶⁹, Bosch L¹⁷⁰, Bontje M¹⁷⁰, Pisters R¹⁷², de Vries TAC¹⁷².
- 6

7 Affiliations

- 8 1. Department of Cardiology, Division of Heart and Lungs, University Medical Center Utrecht, University of
- 9 Utrecht, Utrecht, the Netherlands
- 10 2. Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University,
- 11 Utrecht, the Netherlands
- 12 3. The Dutch Network for Cardiovascular Research (WCN), Utrecht the Netherlands
- 13 4. Department I for Internal Medicine, University Hospital of Cologne, University of Cologne, Cologne,
- 14 Germany
- 15 5. German Center for Infection Research (DZIF), Brunswick, Germany
- 16 6. National Institute for Health University College London Hospitals, London Research Biomedical Research
- 17 Centre, United Kingdom
- 18 7. Health Data Research UK and Institute of Health Informatics, University College London, London, United
- 19 Kingdom
- 20 8. The Hatter Cardiovascular Institute, University College London, London, United Kingdom
- 21 9. Institute of Cardiovascular Science, Faculty of Population Health Sciences, University College London,
- 22 London, United Kingdom
- 23 10. Durrer Center, Netherlands Heart Institute, Utrecht, the Netherlands
- 24 11. Department of Cardiology, Amphia Hospital, the Netherlands
- 25 12. Department of Cardiology, Erasmus MC University Medical Center, Rotterdam, the Netherlands
- 26 13. Department of Intensive Care, Erasmus MC University Medical Center, Rotterdam, the Netherlands
- 27 14. Department of Cardiology, Maasstad Hospital, Rotterdam, the Netherlands
- 28 15. Department of Respiratory and Acute Medicine, Northumbria HealthCare NHS Foundation Trust,
- 29 Newcastle, United Kingdom
- 30 16. Department of Cardiology, Northumbria HealthCare NHS Foundation Trust, Newcastle, United Kingdom
- 31 17. Barts NIHR Biomedical Research Centre, William Harvey Research Institute, Queen Mary University of
- 32 London, United Kingdom
- 33 18. School of Medicine, Technical University of Munich, Department of Internal Medicine II, University
- 34 Hospital rechts der Isar, Munich, Germany
- 35 19. Department of Cardiovascular Sciences, University of Leicester and Cardiovascular Theme, NIHR Leicester
- 36 Biomedical Research Centre, Glenfield Hospital, Leicester, United Kingdom
- 37 20. Department of Infectious Diseases and Infection Control, Ingolstadt Hospital, Ingolstadt, Germany
- 38 21. Department of Cardiology, University Hospital of Geneva, Geneva, Switzerland
- 39 22. Internal Medicine II, Department of Infectious Diseases, Freiburg University Hospital, Freiburg, Germany
- 40 23. Leeds Institute for Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, United Kingdom

- 1 24. Clinic for Pneumology, Infectiology, Internal Medicine and Intensive Care, Hospital Dortmund gGmbH,
- 2 Dortmund, Germany
- 3 25. Department of Clinical Biochemistry, King Fahd Hospital of the University, Imam Abdulrahman Bin Faisal
- 4 University, Alkhobar, Saudi Arabia
- 5 26. Department of Cardiology, King Fahd Hospital of the University, Imam Abdulrahman Bin Faisal
- 6 University, Alkhobar, Saudi Arabia
- 7 27. Department of Pathology, King Fahd Hospital of the University, Imam Abdulrahman Bin Faisal University,
- 8 Alkhobar, Saudi Arabia
- 9 28. Department of Emergency Medicine, King Fahd Hospital of the University, Imam Abdulrahman Bin Faisal
- 10 University, Alkhobar, Saudi Arabia
- 11 29. Department of Critical Care, King Fahd Hospital of the University, Imam Abdulrahman Bin Faisal
- 12 University, Alkhobar, Saudi Arabia
- 13 30. Department of Internal Medicine, King Fahd Hospital of the University, Imam Abdulrahman Bin Faisal
- 14 University, Alkhobar, Saudi Arabia
- 15 31. Emergency Department, University Hospital Regensburg, Regensburg, Germany
- 16 32. NIHR Exeter Clinical Research Facility, Royal Devon and Exeter Hospital and University of Exeter College
- 17 of Medicine & Health, Exeter, United Kingdom
- 18 33. Department of Internal Medicine II, Hematology and Medical Oncology, University Hospital Jena, Jena,

19 Germany

- 20 34. Department of Cardiology, Franciscus Gasthuis, Rotterdam, the Netherlands
- 21 35. Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University
- 22 Frankfurt, Frankfurt am Main, Germany
- 23 36. Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University
- 24 Medical Center, Maastricht, the Netherlands
- 25 37. Department of Cardiovascular Sciences, Centre for Molecular and Vascular Biology, KU Leuven, Belgium
- 26 38. The Netherlands Heart Institute, NL-HI, Utrecht, The Netherlands
- 27 39. Department of Intensive Care, Maastricht University Medical Centre+, Maastricht University, Maastricht,
- 28 Netherlands
- 29 40. Department of Internal Medicine, Division of General Internal Medicine, Section Geriatric Medicine,
- 30 Maastricht University Medical Center+, Maastricht, The Netherlands
- 31 41. Department of Internal Medicine II, Passau Hospital, Passau, Germany
- 32 42. World-Class Research Center Digital biodesign and personalized healthcare, I.M. Sechenov First Moscow
- 33 State Medical University, Sechenov University, Moscow, Russia
- 34 43. Department of Faculty Therapy No. 1 of N.V. Sklifosovsky Institute for Clinical Medicine, I.M. Sechenov
- 35 First Moscow State Medical University, Sechenov University, Moscow, Russia
- 36 44. University of Bochum, University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care,
- 37 Minden, Germany
- 38 45. Amsterdam University Medical Center, University of Amsterdam, Heart Center; Department of Clinical and
- 39 Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands

- 1 46. Amsterdam University Medical Center, University of Amsterdam, Department of Clinical Epidemiology,
- 2 Biostatistics & Bioinformatics, Amsterdam, the Netherlands
- 3 47. Klinikum Bremen-Mitte, Department of Internal Medicine I, Bremen, Germany
- 4 48. Department of Cardiology, St. Antonius Hospital, Nieuwegein, the Netherlands
- 5 49. Department of Gastroenterology, University Hospital Augsburg, Augsburg, Germany
- 6 50. Department of Cardiology, Catharina Hospital, Eindhoven, the Netherlands
- 7 51. Department of Educational Development and Research in the Faculty of Health, Medicine and Life
- 8 Sciences, Catharina Hospital, Eindhoven, the Netherlands
- 9 52. Department of Gastroenterology and Infectiology, Hospital Ernst-von-Bergmann, Potsdam, Germany
- 10 53. Department of Medical Microbiology and Infectious Diseases, Erasmus MC, University Medical Center,
- 11 Rotterdam, the Netherlands
- 12 54. Department of Infectious Diseases, University Hospital Essen, University Duisburg Essen, Essen, Germany
- 13 55. Department of Cardiology, HeartLungCenter, Leiden University Medical Center, Leiden, the Netherlands
- 14 56. Department of Internal Medicine III, Ludwig Maximilians University, Munich, Germany
- 15 57. German Cancer Consortium (DKTK), partner site Munich, Munich, Germany
- 16 58. Bavarian Center for Cancer Research (BZKF), Munich, Germany
- 17 59. Department of Cardiology, Gelre Hospital Apeldoorn, Apeldoorn, the Netherlands
- 18 60. Department of Gastroenterology and Infectiology, Heidelberg University Hospital, Heidelberg, Germany
- 19 61. Department of Cardiology, St. Jansdal Hospital, Harderwijk, the Netherlands
- 20 62. Robert-Bosch Hospital, Department of Gastroenterology, Hepatology and Endocrinology, Stuttgart,
 21 Germany
- ET Germany
- 22 63. Department of Cardiology, Vrije Universiteit Amsterdam, Amsterdam Cardiovascular Sciences,
- 23 Amsterdam, the Netherlands
- 24 64. Department of Cardiology, Dijklander Hospital, Hoorn, the Netherlands
- 25 65. Department of Internal Medicine II, Division of Infectious Diseases, University Hospital Würzburg,
- 26 Würzburg, Germany
- 27 66. Department of Cardiology, Elizabeth-TweeSteden Hospital, Tilburg, the Netherlands
- 28 67. Division of Infectious Diseases, Department I of Internal Medicine, University Hospital of Cologne,
- 29 University of Cologne, Cologne, Germany
- 30 68. German Center for Infection Research, Partner Site Bonn-Cologne, Cologne, Germany
- 31 69. Royal Free London NHS Foundation Trust, London, United Kingdom
- 32 70. William Harvey Research Institute, Queen Mary University of London, United Kingdom
- 33 71. Department of Intensive Care Medicine, Royal Free Hospital, Royal Free London NHS Foundation Trust,
- 34 London, United Kingdom
- 35 72. Department of General, Visceral and Transplant Surgery, University Hospital Tübingen, Tübingen,
- 36 Germany
- 37 73. Department of Cardiology, Hospital Group Twente, Almelo, the Netherlands
- 38 74. Department of Intensive Care, Hospital Group Twente, Almelo, the Netherlands
- 39 75. Department of Pulmonology, Hospital Group Twente, Almelo, the Netherlands
- 40 76. Municipal Hospital Karlsruhe, Karlsruhe, Germany

- 1 77. Department of Cardiology, Deventer Hospital, Deventer, the Netherlands
- 2 78. Medical Clinic I, University Hospital Erlangen, Erlangen, Germany
- 3 79. Department of Cardiology, Freeman Hospital and Newcastle University, Newcastle upon Tyne NHS
- 4 Foundation Trust, United Kingdom
- 5 80. Department of Cardiothoracic Services, Freeman Hospital and Newcastle University, Newcastle upon Tyne
- 6 NHS Foundation Trust, United Kingdom
- 7 81. National Heart and Lung Institute, Imperial College, London, United Kingdom
- 8 82. Royal Brompton Hospital, London, United Kingdom
- 9 83. University Hospital Ulm, Division of Infectious Diseases, Clinic of Internal Medicine III
- 10 84. Department of Cardiology, Jeroen Bosch Hospital, 's-Hertogenbosch, the Netherlands
- 11 85. 4th Department of Internal Medicine, Hospital Leverkusen gGmbH, Leverkusen, Germany
- 12 86. Intensive Care Department, Salford Royal NHS Foundation Trust, Salford, United Kingdom
- 13 87. Division of Cardiology, Hospital Maria Hilf Mönchengladbach, Mönchengladbach, Germany
- 14 88. Department of Cardiology, Zaans Medical Center, Zaandam, The Netherlands
- 15 89. Department of Neurology, Katholisches Klinikum Bochum, Ruhr University Bochum, Bochum, Germany
- 16 90. Department of Cardiology, Meander Medical Center, Amersfoort, the Netherlands
- 17 91. Bundeswehr Central Hospital, Koblenz, Germany
- 18 92. Department of Cardiology, Haaglanden Medical Center, the Hague, the Netherlands
- 19 93. Evangelical City Hospital Saarbrücken, Saarbrücken, Germany
- 20 94. Department of Cardiology, Groene Hart Hospital, Gouda, the Netherlands
- 21 95. Tropical Clinic Paul-Lechler Hospital Tübingen, Tübingen, Germany
- 22 96. Department of Cardiology, A.O.U. San Luigi Gonzaga, Orbassano, Turin, Italy
- 23 97. Electrophysiology Unit, Department of Cardiology, A.O.U. San Luigi Gonzaga, Orbassano, Turin, Italy
- 24 98. Intensive Coronary Care Unit, Department of Cardiology, A.O.U. San Luigi Gonzaga, Orbassano, Turin,

25 Italy

- 26 99. Medical Department I, Marien Hospital Herne, Ruhr-University Bochum, Germany
- 27 100. Department of Cardiovascular Research, Tehran Heart Center, Cardiovascular Diseases Research Institute,
- 28 Tehran University of Medical Sciences, Tehran, Iran
- 29 101. Department of Cardiology, Tehran Heart Center, Cardiovascular Diseases Research Institute, Tehran
- 30 University of Medical Sciences, Tehran, Iran
- 31 102. Department of Nursing, Tehran Heart Center, Cardiovascular Diseases Research Institute, Tehran
- 32 University of Medical Sciences, Tehran, Iran
- 33 103. Department of Interventional Cardiology, Tehran Heart Center, Cardiovascular Diseases Research
- 34 Institute, Tehran University of Medical Sciences, Tehran, Iran
- 35 104. Department of Gastroenterology, Hepatology and Infectious Diseases, University Hospital Düsseldorf,
- 36 Heinrich-Heine-University, Düsseldorf, Germany
- 37 105. Department of Cardiology, CHU UCL Namur site Godinne, Université Catholique de Louvain, Yvoir,
- 38 Belgium
- 39 106. Department of Infectious Diseases and Clinical Microbiology, Hacettepe University School of Medicine,
- 40 Ankara, Turkey

- 1 107. Department of Cardiology, Zuyderland Medical Center, Heerlen, the Netherlands
- 2 108. Department of Internal Medicine, Hematology and Oncology, Elbland Hospital Riesa, Riesa, Germany
- 3 109. Department of Cardiology, Heart Center Hasselt, Jessa Hospital, Hasselt, Belgium
- 4 110. Department of Infectious Diseases & Immunity, Jessa Hospital, Hasselt, Belgium
- 5 111. Faculty of Medicine and Life Sciences, Hasselt University, Hasselt, Belgium
- 6 112. Department of Internal Medicine I, University Medical Center Schleswig-Holstein, Kiel, Germany
- 7 113. Department of Cardiology, Medical Center Leeuwarden (MCL), Leeuwarden, the Netherlands
- 8 114. Department of Medicine II, Section of Infectious Diseases, Justus-Liebig-University Giessen, Germany,
- 9 member of the German Lung Center (DZL)
- 10 115. Intensive Care Unit, Hospital do Espírito Santo, Évora, Portugal
- 11 116. Division of Infectious Diseases, University Hospital Carl Gustav Carus, Technical University of Dresden,
- 12 Dresden, Germany
- 13 117. Department of Cardiology, Franciscus Vlietland, Schiedam, The Netherlands
- 14 118. Medical Clinic V, Nephrology, Rheumatology, Blood Purification, Academic Teaching Hospital
- 15 Braunschweig, Braunschweig, Germany
- 16 119. Arrhythmias Unit, Department of Cardiology, Hospital Universitario Virgen de las Nieves, Granada, Spain
- 17 120. Munich Clinic Schwabing, Munich, Germany
- 18 121. Department of Cardiology, E.M.M.S Hospital, Nazareth, Israel
- 19 122. Section of Fibrotic Lung Diseases, University Hospital Giessen and Marburg, Giessen Campus, Justus
- 20 Liebig University Giessen, University of Giessen Marburg Lung Center, as well as the Fulda Campus of the
- 21 Medical University of Marburg, Med. Clinic V, Member of German Center for Lung Research Giessen,
- 22 Germany
- 23 123. Department of Cardiology, Admiraal de Ruyter Hospital, Goes, the Netherlands
- 24 124. Agaplesion Diaconia Hospial Rotenburg, Rotenburg, Germany
- 25 125. Department of Internal Medicine, Antonius Hospital, Sneek, the Netherlands
- 26 126. Department of Pneumology, Allergy, Sleep and Intensive Care Medicine, Petrus Hospital Wuppertal,
- 27 University of Witten-Herdecke, Wuppertal, Germany
- 28 127. Department of Cardiology, Hospital Professor Doutor Fernando Fonseca, Amadora, Portugal
- 29 128. Elisabeth Hospital, Essen, Germany
- 30 129. Department of Cardiology, Albert Schweitzer Hospital, Dordrecht, the Netherlands
- 31 130. Malteser Hospital St. Franziskus-Hospital Flensburg, Flensburg, Germany
- 32 131. Department of Internal Medicine, Clinic University Hospital, INCLIVA Health Research Institute,
- 33 Valencia, Spain
- 34 132. Department of Medicine, School of Medicine, University of Valencia, Valencia, Spain
- 35 133. Sophien- and Hufeland Clinic Weimar, Weimar, Germany
- 36 134. Department of Cardiology, van Weel-Bethesda Hospital, Dirksland, the Netherlands
- 37 135. Department of Internal Medicine I, Department of Gastroenterology, Hepatology, Nephrology,
- 38 Infectiology, Endocrinology and Diabetology, University Hospital Bonn, Bonn, Germany
- 39 136. Department of Intensive Care, Rode Kruis Hospital, Beverwijk, the Netherlands
- 40 137. Department of Cardiology, Rode Kruis Hospital, Beverwijk, the Netherlands

- 1 138. Helios Hospital Pirna, Pirna, Germany
- 2 139. Department of Pulmonology, Antwerp University Hospital, Edegem, Belgium
- 3 140. Department of General Internal Medicine, Infectious Diseases and Tropical Medicine, Antwerp University
- 4 Hospital, Edegem, Belgium
- 5 141. Department of Cardiology, Antwerp University Hospital, Edegem, Belgium
- 6 142. Hospital St. Joseph-Stift Dresden, Dresden, Germany
- 7 143. Department of Cardiology, AZ Maria Middelares, Ghent, Belgium
- 8 144. Department of Internal Medicine, Ghent University, Ghent, Belgium
- 9 145. Oberlausitz Hospital, Germany
- 10 146. Department of Cardiology, Saxenburgh Medical Center, Hardenberg, the Netherlands
- 11 147. Craigavon Area Hospital, Southern Care & Social Care Trust Hospitals, Portadown, Northern Ireland
- 12 148. Benha Faculty of Medicine, Benha, Egypt
- 13 149. Department of Cardiology, SSR Val Rosay, Saint Didier au Mont d'Or, France
- 14 150. Department of Pulmonology, Bravis Hospital, Roosendaal, the Netherlands
- 15 151. Department of Cardiology, Bravis Hospital, Roosendaal, the Netherlands
- 16 152. Department of Intensive Care, Martini Hospital, Groningen, the Netherlands
- 17 153. Department of Cardiology, LangeLand Hospital, Zoetermeer, the Netherlands
- 18 154. Department of Pulmonology, Medisch Spectrum Twente, Enschede, the Netherlands
- 19 155. Derpartment of Internal Medicine and Infectious Diseases, Medisch Spectrum Twente, Enschede, the
- 20 Netherlands
- 21 156. Department of Cardiology, Thorax Center Twente, Medisch Spectrum Twente, Enschede, the Netherlands
- 22 157. Department of Cardiology, Bernhoven Hospital, Uden, the Netherlands
- 23 158. Department of Cardiology, CHVZ, University Hospital Brussels, Jette, Belgium
- 24 159. Department of Cardiology, Isala Hospital, Zwolle, the Netherlands
- 25 160. Department of Cardiology, Ikazia Hospital, Rotterdam, the Netherlands
- 26 161. Department of Cardiology, Gelre Hospital Zutphen, Zutphen, the Netherlands
- 27 162. Department of Gynecology, Amstelland Hospital, Amstelveen, the Netherlands
- 28 163. Department of Cardiology, Slingeland Hospital Doetinchem, the Netherlands
- 29 164. Department of Cardiology, Treant Zorggroep, Emmen, the Netherlands
- 30 165. NIHR Bristol Cardiovascular Biomedical Research Centre, Cardiac Magnetic Resonance Department,
- 31 Bristol Heart Institute, University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom
- 32 166. University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom
- 33 167. Bristol Medical School, University of Bristol, Bristol, United Kingdom
- 34 168. Department of Cardiology, Beatrix Hospital, Gorinchem, the Netherlands
- 35 169. Department of Cardiology, Spaarne Gasthuis, Haarlem, the Netherlands
- 36 170. Department of Cardiology, Diakonessenhuis, Utrecht, the Netherlands
- 37 171. Department of Pulmonology, Diakonessenhuis, Utrecht, the Netherlands
- 38 172. Department of Cardiology, Rijnstate Hospital, Arnhem, the Netherlands
- 39 173. Barts Life Sciences, Barts Health NHS Trust, London, United Kingdom

- 1 174. Department of Internal Medicine, Hematology and Oncology, Goethe University Frankfurt, Frankfurt,
- 2 Germany
- 3 175. Department of Cardiology, University Medical Center Groningen, Groningen, the Netherlands
- 4 176. Department of Cardiology, Martini Hospital, Groningen, the Netherlands
- 5 177. Department of Cardiology, Functional and and Ultrasound Diagnostics of N.V. Sklifosovsky Institute for
- 6 Clinical Medicine, I.M. Sechenov First Moscow State Medical University, Sechenov University, Moscow,
- 7 Russia
- 8 178. Department of Emergency, Tehran Heart Center, Cardiovascular Diseases Research Institute, Tehran
- 9 University of Medical Sciences, Tehran, Iran
- 10 179. Department of Cardiology, One Day Surgery Hospital, Cairo, Egypt
- 11 180. COVID-19 Unit, SSR Val Rosay, Saint Didier au Mont d'Or, France
- 12 181. Department of Rheumatology and Clinical Immunology, Medisch Spectrum Twente, Enschede, the
- 13 Netherlands
- 14 182. Research Department, Bernhoven Hospital, Uden, the Netherlands
- 15 183. Department of Cardiology, Amstelland Hospital, Amstelveen, the Netherlands

16